Fully-automated production of [68Ga]Ga-PentixaFor on the module Modular Lab-PharmTracer

BACKGROUND: PentixaFor is a promising radiopharmaceutical for positron emission tomography in the detection of different tumor entities and other diseases. Until now, the synthesis of [68Ga]Ga-PentixaFor was reported for the automated synthesis module from Scintomics® only. Our aim was to evaluate the automated synthesis of this radiopharmaceutical on a different module in order to make it available for a broader community. RESULTS: The synthesis of [68Ga]Ga-PentixaFor with different amounts of PentixaFor (50 μg, 30 μg and 20 μg) on the Modular Lab PharmTracer (MLPT) from Eckert & Ziegler with the already established synthesis template for [68Ga]Ga-DOTATOC yielded best results with 50 μg PentixaFor for clinical multi-dose application. All different quality control parameters tested (e.g. sterility, stability and radiochemical purity) were in accordance with the European Pharmacopoeia. CONCLUSIONS: [68Ga]Ga-PentixaFor was successfully synthesized fully-automated on the synthesis module Modular Lab PharmTracer and can be used for multi-dose application in clinical settings

Erinnerungskultur und Erinnerungspflicht

Festakt : 10 Jahre Historisch Orientierte Kulturwissenschaften an der Universität des Saarlandes : 16. Mai 2009

Zur Geschichte der Fachzeitschriften: von der "Historischen Zeitschrift" zu den "zeitenblicken"

"The article spans a large spectrum between the "classical style" periodicals and the new e-journals. First our attention is drawn to the beginnings of scientific journals which in the late 19th century were developing from university-standard periodicals to differentiated specialist bodies with a very broad offer of information. Taking the "Historische Zeitung" as an example, the individual stations of passage of the print periodicals are traced. Do print periodicals belong to the past, are e-journals the promise of the future? The article closes with an ambivalent conclusion: Whereas the periodical crisis and technical possibilities would on the one hand seem to render e-journals as the most suitable and trendsetting medium for specialist information, traditional reception forms and scepticism towards the 'volatile' form of electronic publishing are still opposed to a broad use of such periodicals. It will take another few years before we can see to what extent this scepticism can be overcome." (author's abstract)"Der Beitrag spannt einen weiten Bogen von den Zeitschriften 'klassischen Stils' bis hin zu den neuen E-Journalen. Zunächst wird der Blick auf die Anfänge der wissenschaftlichen Zeitschriften gelenkt, die sich Ende des 19. Jahrhunderts von den jeweiligen Universitäts-Standard präsentierenden Periodika zu Zeitschriften der sich ausdifferenzierenden Fachinstitutionen mit einem sehr breiten Informationsspektrum entwickelten. Am Beispiel der 'Historischen Zeitschrift' werden die einzelnen Entwicklungsphasen einer Printzeitschrift nachgezeichnet. Gehören Printprodukte der Vergangenheit an? Sind E-Journals ein Versprechen für die Zukunft? Der Artikel schließt mit einem ambivalenten Fazit: Während die Krise der Periodika und die technischen Möglichkeiten einerseits die E-Journale zum geeignetsten und zukunftsweisenden Medium für Spezialisteninformationen machen, stehen traditionelle Lese- und Arbeitsgewohnheiten sowie ein gewisser Skeptizismus gegenüber der 'flüchtigen' Form elektronischen Publizierens einer breiten Verwendung solcher Periodika noch entgegen. Es wird wohl noch einige Jahre dauern, bis sich zeigt, inwieweit dieser Skeptizismus überwunden werden kann." (Autorenreferat

Novi izvori za povijest slavonske seljačke bune 1573.

Posljednjih se godina znatno povećao broj izvora z a povijest seljačkebune iz 1572/73 godine. U usporedbi s ranije objavljenim izvorima Kro-nesa, Račkog, von Zahna i Mella pojavila se tijekom priprema za proslavu 400-te godišnjice bune iznenađujuća količina izvora koja je naročitopovećala naša znanja o događajima što su prethodili ustanku, te o privrednim uvjetima na ustaničkom području. Tu, prije svega, treba upozoriti na istraživanja i izdavačku djelatnost Josipa Adamčeka koji je zaslužan i za predradnje oko ediranja i za ukupne sinteze

Induction of sustained remission in early inflammatory arthritis with the combination of infliximab plus methotrexate: the DINORA trial.

BACKGROUND: In the present study, we explored the effects of immediate induction therapy with the anti-tumour necrosis factor (TNF)α antibody infliximab (IFX) plus methotrexate (MTX) compared with MTX alone and with placebo (PL) in patients with very early inflammatory arthritis. METHODS: In an investigator-initiated, double-blind, randomised, placebo-controlled, multi-centre trial (ISRCTN21272423, http://www.isrctn.com/ISRCTN21272423 ), patients with synovitis of 12 weeks duration in at least two joints underwent 1 year of treatment with IFX in combination with MTX, MTX monotherapy, or PL randomised in a 2:2:1 ratio. The primary endpoint was clinical remission after 1 year (sustained for at least two consecutive visits 8 weeks apart) with remission defined as no swollen joints, 0-2 tender joints, and an acute-phase reactant within the normal range. RESULTS: Ninety patients participated in the present study. At week 54 (primary endpoint), 32% of the patients in the IFX + MTX group achieved sustained remission compared with 14% on MTX alone and 0% on PL. This difference (p < 0.05 over all three groups) was statistically significant for IFX + MTX vs PL (p < 0.05), but not for IFX + MTX vs MTX (p = 0.10), nor for MTX vs PL (p = 0.31). Remission was maintained during the second year on no therapy in 75% of the IFX + MTX patients compared with 20% of the MTX-only patients. CONCLUSIONS: These results indicate that patients with early arthritis can benefit from induction therapy with anti-TNF plus MTX compared with MTX alone, suggesting that intensive treatment can alter the disease evolution. TRIAL REGISTRATION: The trial was registered at http://www.isrctn.com/ISRCTN21272423 on 4 October 2007 (date applied)/12 December 2007 (date assigned). The first patient was included on 24 October 2007

BCMA x CD3 T-cell engager in a patient with penta-refractory multiple myeloma and HIV: a clinical and immunological report

Not available